Andreas Diefenbach

Andreas Diefenbach

Auto-generated profile, based on publicly available information

Andreas Diefenbach

Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin 1 Department of Microbiology, Infectious Diseases and Immunology Berlin

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Nature Immunology
Verified
Journal Article
Open access
PDF file
LRLucas Rebuffet
Lucas Rebuffet
JMJanine E. Melsen
Janine E. Melsen
BEBertrand Escalière
Bertrand Escalière
DBDaniela Basurto-Lozada
Daniela Basurto-Lozada
ABAvinash Bhandoola
Avinash Bhandoola
ÉVÉric Vivier
Éric Vivier
Natural killer (NK) cells are innate lymphoid cells (ILCs) contributing to immune responses to microbes and tumors. Historically, their classification hinged on a limited array of surface protein markers. Here, we used single-cell RNA sequencing (scRNA-seq) and cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to dissect the heterogeneity of NK cells. We identified three prominent NK cell subsets in healthy human blood: NK1, NK2 and NK3, further differentiated into six distinct subgroups. Our findings delineate the molecular characteristics, key transcription factors, biological functions, metabolic traits and cytokine responses of each subgroup. These data also suggest two separate ontogenetic origins for NK cells, leading to divergent transcriptional trajectories. Furthermore, we analyzed the distribution of NK cell subsets in the lung, tonsils and intraepithelial lymphocytes isolated from healthy individuals and in 22 tumor types. This standardized terminology aims at fostering clarity and consistency in future research, thereby improving cross-study comparisons.

30 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
KGKonrad Gronke
Konrad Gronke
PHPedro P. Hernández
Pedro P. Hernández
JZJakob Zimmermann
Jakob Zimmermann
CKChristoph S. N. Klose
Christoph S. N. Klose
MKMichael Kofoed-Branzk
Michael Kofoed-Branzk
ADAndreas Diefenbach
Andreas Diefenbach

25 October 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MWMario Witkowski
Mario Witkowski
CTCaroline Tizian
Caroline Tizian
MFMarta Ferreira-Gomes
Marta Ferreira-Gomes
DNDaniela Niemeyer
Daniela Niemeyer
TJTerry Jones
Terry Jones
ADAndreas Diefenbach
Andreas Diefenbach

1 May 2020 in Cell
Verified
Journal Article
Closed access
LSLaura Schaupp
Laura Schaupp
SMSabine Muth
Sabine Muth
LRLeif Rogell
Leif Rogell
MKMichael Kofoed-Branzk
Michael Kofoed-Branzk
FMFelix Melchior
Felix Melchior
HPHans Christian Probst
Hans Christian Probst

15 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ASArne Sattler
Arne Sattler
ESEva Vanessa Schrezenmeier
Eva Vanessa Schrezenmeier
UWUlrike A. Weber
Ulrike A. Weber
APAlexander Potekhin
Alexander Potekhin
FBFriederike Bachmann
Friederike Bachmann
KKKatja Kotsch
Katja Kotsch
Novel mRNA-based vaccines have been proven to be powerful tools in combating the global pandemic caused by SARS-CoV-2, with BNT162b2 (trade name: Comirnaty) efficiently protecting individuals from COVID-19 across a broad age range. Still, it remains largely unknown how renal insufficiency and immunosuppressive medication affect development of vaccine-induced immunity. We therefore comprehensively analyzed humoral and cellular responses in kidney transplant recipients after the standard second vaccination dose. As opposed to all healthy vaccinees and the majority of hemodialysis patients, only 4 of 39 and 1 of 39 transplanted individuals showed IgA and IgG seroconversion at day 8 ± 1 after booster immunization, with minor changes until day 23 ± 5, respectively. Although most transplanted patients mounted spike-specific T helper cell responses, frequencies were significantly reduced compared with those in controls and dialysis patients and this was accompanied by a broad impairment in effector cytokine production, memory differentiation, and activation-related signatures. Spike-specific CD8+ T cell responses were less abundant than their CD4+ counterparts in healthy controls and hemodialysis patients and almost undetectable in transplant patients. Promotion of anti-HLA antibodies or acute rejection was not detected after vaccination. In summary, our data strongly suggest revised vaccination approaches in immunosuppressed patients, including individual immune monitoring for protection of this vulnerable group at risk of developing severe COVID-19.

30 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFMarta Ferreira-Gomes
Marta Ferreira-Gomes
AKAndrey Kruglov
Andrey Kruglov
PDPawel Durek
Pawel Durek
FHFrederik Heinrich
Frederik Heinrich
CTCaroline Tizian
Caroline Tizian
MMMir-Farzin Mashreghi
Mir-Farzin Mashreghi
The pathogenesis of severe COVID-19 reflects an inefficient immune reaction to SARS-CoV-2. Here we analyze, at the single cell level, plasmablasts egressed into the blood to study the dynamics of adaptive immune response in COVID-19 patients requiring intensive care. Before seroconversion in response to SARS-CoV-2 spike protein, peripheral plasmablasts display a type 1 interferon-induced gene expression signature; however, following seroconversion, plasmablasts lose this signature, express instead gene signatures induced by IL-21 and TGF-β, and produce mostly IgG1 and IgA1. In the sustained immune reaction from COVID-19 patients, plasmablasts shift to the expression of IgA2, thereby reflecting an instruction by TGF-β. Despite their continued presence in the blood, plasmablasts are not found in the lungs of deceased COVID-19 patients, nor does patient IgA2 binds to the dominant antigens of SARS-CoV-2. Our results thus suggest that, in severe COVID-19, SARS-CoV-2 triggers a chronic immune reaction that is instructed by TGF-β, and is distracted from itself.